Unanticipated improvement in seizure control in drug-resistant epilepsy - real world observations by Moloney, Patrick B. & Costello, Daniel J.
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title Unanticipated improvement in seizure control in drug-resistant epilepsy
- real world observations
Author(s) Moloney, Patrick B.; Costello, Daniel J.
Publication date 2020-11-21
Original citation Moloney, P. B. and Costello, D. J. (2020) 'Unanticipated improvement in
seizure control in drug-resistant epilepsy - real world observations',
Seizure - European Journal of Epilepsy. doi:
10.1016/j.seizure.2020.11.005




Access to the full text of the published version may require a
subscription.
Rights © 2020, Elsevier B.V. All rights reserved. This manuscript version is
made available under the CC BY-NC-ND 4.0 license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
Embargo information Access to this article is restricted until 12 months after publication by
request of the publisher.






Unanticipated improvement in seizure control in drug-resistant epilepsy-
real world observations




To appear in: Seizure: European Journal of Epilepsy
Received Date: 1 September 2020
Revised Date: 8 November 2020
Accepted Date: 10 November 2020
Please cite this article as: {doi: https://doi.org/
This is a PDF file of an article that has undergone enhancements after acceptance, such as
the addition of a cover page and metadata, and formatting for readability, but it is not yet the
definitive version of record. This version will undergo additional copyediting, typesetting and
review before it is published in its final form, but we are providing this version to give early
visibility of the article. Please note that, during the production process, errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal
pertain.
© 2020 Published by Elsevier.
 1 
Title Page 
Title: Unanticipated improvement in seizure control in drug-resistant epilepsy- real world observations  
Authors: 
Patrick B. Moloney MRCPI1  
Daniel J. Costello MD MRCPI1,2 Corresponding author 
1. Department of Neurology, Cork University Hospital 
2. College of Medicine and Health, University College Cork, Ireland.   
 
Corresponding author address and contact details: 
Department of Neurology, 






Word count (including abstract): 3414 + 294 (abstract)= 3708 
Character count for title: 97 
Number of references: 34 
Number of tables: 4 (+ 2 in supplementary materials) 





 Drug-resistant epilepsy (DRE) occurs in a third of patients 
 The value of serial anti-seizure medication (ASM) trials in DRE is controversial 
 A retrospective study of unanticipated ASM responders in a DRE cohort 















To determine the clinical features and anti-seizure medication (ASM) strategies associated with an 
unanticipated substantial improvement in seizure control in patients with drug-resistant epilepsy (DRE). 
Methods:  
This retrospective analysis of patients attending a tertiary care epilepsy clinic between 2008 and 2017 
identified all patients with active DRE (at least 1 seizure per month for 6 months, despite treatment with 
2 different ASMs). All treatment interventions were recorded from when DRE was first identified to the 
end of the study. The primary end points were seizure freedom or meaningful reduction in seizure 
frequency (greater than 75%) sustained for at least 12 months after a treatment intervention. 
Results: 
Three hundred and twenty-two patients were included in the analysis. Overall, 10% became seizure 
free following ASM adjustment and an additional 10% had a greater than 75% improvement in seizure 
control (median follow-up, 4 years). An ASM introduction was ten times more likely than an ASM dose 
increase to improve seizure control. Combined focal and generalized epilepsy, intellectual disability and 
prior treatment with more than 5 ASMs were more frequently observed in those with continued 
pharmacoresistance. ASM responders were more likely to have primary generalized epilepsy. Rational 
polytherapy (combining ASMs with different mechanisms of action) was almost ubiquitous amongst 
ASMs responders (95% taking at least 2 drugs with different mechanistic targets). Of the ASM additions 
that heralded improved seizure control, 85% were maintained at submaximal doses. 
Conclusions: 
This retrospective analysis of a large number of ‘real-world’ patients provides evidence to persist with 
ASM trials in DRE. Early rotation of ASMs if a clinical response is not observed at a substantial dose 
and rational ASM polytherapy may yield better clinical outcomes in patients with DRE, although a 
















Ultimately, more than one third of patients with epilepsy have seizures refractory to anti-seizure 
medications (ASMs), and the likelihood of treatment response diminishes exponentially with sequential 
unsuccessful medication trials.1,2,3  These outcomes remain unchanged, despite the introduction of 
more than a dozen new ASMs in the past twenty years.3 Accordingly, the International League Against 
Epilepsy (ILAE) defined drug-resistant epilepsy (DRE) as ‘failure of adequate trials of two tolerated and 
appropriately chosen and used ASM schedules (whether as monotherapies or in combination) to 
achieve sustained seizure freedom’.4 
 
Prospective data suggests that switching ASMs has little impact on seizure control and that changes in 
seizure frequency are due to spontaneous disease fluctuations.5,6  These prospective studies were 
conducted on patients with infrequent seizures, treated with ASM monotherapy. As such, the 
applicability of these findings to DRE cohorts is questionable and these studies were limited by their 
small sample sizes.  
 
Epilepsy surgery is four times more likely than medical therapy to achieve seizure freedom in DRE.7 
However, a substantial proportion of refractory patients are either ineligible for surgery, cannot access 
surgery or decline surgery. Additionally, approximately one third of patients have persistent seizures 
after epilepsy surgery.8,9 Consequently, for a major proportion of patients with DRE, medications will 
remain the mainstay of treatment.  
 
The reversibility of DRE without surgery has been infrequently studied.  In a prospective study of 
incident childhood-onset DRE, over half the patients eventually became seizure free during 40-year 
median follow-up.10  In adult DRE cohorts, 21-33% became seizure free for at least 12 months following 
medication adjustment.11,12,13,14,15 These studies underscore the rationale to persist with ASM trials in 
apparently DRE. Rational polytherapy is often advocated in DRE but supporting clinical evidence is 











The aim of this study was to determine if unanticipated ASM responders had distinctive clinical 
characteristics when compared with persistent non-responders in a cohort of adult patients with 
heretofore DRE. The strategies and ASM regimens that led to a treatment response were analyzed to 
determine the value of serial ASM trials in DRE.  
 
Methods 
All patients with DRE attending a tertiary care epilepsy center between 2008 and 2017 were identified 
using a patient database. The epilepsy service has a track record of managing patients with DRE, many 
of whom were referred from other neurologists within the region for longitudinal care and consideration 
for epilepsy surgery.   All patients were seen repeatedly by an epileptologist (D.J.C.) during that period. 
DRE was defined using the ILAE consensus statement.4   
 
We included patients with active epilepsy (defined as at least one seizure per month over a minimum 
of six months), aged 16 years or older, on a fixed regimen of ASMs for at least six months prior to the 
study. They required follow-up in the clinic for at least 12 months after their last treatment adjustment. 
Patients with psychogenic non-epileptic seizures (PNES), evidence of poor treatment compliance 
and/or concomitant substance misuse were excluded to reduce the influence of confounding factors on 
treatment response. The diagnosis of epilepsy was made on the basis of detailed clinical assessment 
by the senior author (D.J.C.). In many patients ancillary evidence supportive of a DRE diagnosis was 
available, including routine electroencephalography (EEG) or video-EEG monitoring. 
 
From a total database of 1865 patients attending the service between 2008 and 2017, 322 patients with 
DRE were identified and included in the analysis. Demographic and clinical features when they were 
first determined to be treatment resistant are shown in Table 1. The epilepsy type was classified 
according to the ILAE’s most recent position paper.17  
 
A pragmatic treatment strategy is used in the epilepsy clinic. ASMs are prescribed and adjusted by the 
consultant epileptologist (D.J.C.) until satisfactory seizure frequency is obtained. ASMs are titrated to a 










associated with improved clinical outcomes.18,19 Tolerability is assessed by gradually titrating to an 
interim dose before increasing further to the target dose. The ASM is retained if it improves seizure 
frequency or severity. The duration of each trial varies depending on the baseline seizure frequency 
but in general there is early rotation of ASMs if they are deemed to be inefficacious. Polypharmacy (use 
of 3 or more ASMs) is avoided where possible, in an effort to minimize side effects. In those with highly 
active refractory epilepsy, abolition of convulsive or dangerous seizures is targeted, in an effort to 
reduce the risk of seizure-related injuries and sudden unexpected death in epilepsy (SUDEP). 
 
We recorded all treatment interventions, from the date when DRE was first identified to the end of the 
study period. Treatment interventions included: drug introductions; drug withdrawals; dose increases; 
surgery; and vagal nerve stimulation (VNS). We classified a therapeutic intervention as a ‘dose 
increase’ when an ASM dose was increased after a period of 6 months or longer on a target dose.  
 
Treatment response was ascertained from the patient’s medical record and clinic letters. Generally, the 
baseline seizure frequency was recorded prior to a therapeutic intervention and the response 
documented in the follow-up clinic letter. If there was insufficient clinical information to accurately 
quantify seizure frequency following an intervention, the intervention was excluded from the analysis. 
The primary end points were seizure freedom or greater than 75% reduction in seizure frequency 
following a therapeutic intervention for at least 12 months. These high threshold endpoints in patients 
with a baseline seizure frequency of at least 1 seizure per month were chosen to avoid ambiguous 
treatment responses. Patients who reached the primary endpoints following drug interventions were 
categorized as ‘ASM responders’.  
 
Statistical analysis 
Descriptive analysis of clinical characteristics was performed. All data were regarded as non-parametric 
and comparison between groups was by chi square test for categorical data and Mann-Whitney for 











Standard protocol approvals, registrations, and patient consents 
The data for this study were retrospectively collected and analyzed. The ethics committee of our 
institution approved this study, and considering the observational nature of the study, patient consent 




Amongst our cohort of 322 DRE patients, 626 ASM introductions, 194 ASM dose increases, 33 epilepsy 
surgeries and 11 VNS procedures were recorded. The response rates for each intervention are shown 
in Table 2. Epilepsy surgery was most likely to render patients seizure free at 12 months (15/33 or 
45.45%), with an additional 10 epilepsy surgery patients experiencing a greater than 75% reduction 
(10/33 or 30.3%). Approximately 5% of individual ASM introductions were associated with seizure 
freedom at 12 months. The introduction of a new ASM was ten times more likely than an ASM dose 
increase to be associated with seizure freedom or a greater than 75% reduction in seizure frequency, 
12 months after the intervention. A total of 66 patients (or 20.5% of the overall DRE cohort) had a 
greater than 75% reduction in seizure frequency one year after a medication intervention, of whom 50%  
(n=33) were seizure free. An additional 25 patients (or 7.76% of the overall DRE cohort) achieved this 
primary end point one year after epilepsy surgery. Twelve of the 25 (48%) epilepsy surgery responders 
had mesial temporal sclerosis. 
 
Comparisons made between ASM responders and those who failed to experience meaningful seizure 
reductions are shown in Table 3. A greater proportion of ASM responders had primary generalized 
epilepsy compared with those who didn’t respond (21.21% compared with 6.49%; p=0.0004). Twenty-
eight of the 29 (96.55%) patients classified as having primary generalized epilepsy had seizures and 
interictal electroencephalographic discharges consistent with their diagnosis. No ASM responders with 
primary generalized epilepsy were treated with ASMs known to exacerbate generalized seizures, prior 
to their inclusion in the study (see Table 1 in supplementary materials). Of note, 2 patients with 











Non-responders were more likely to have combined generalized and focal epilepsy with multiple seizure 
types (22.94% compared with 1.52%; p=0.0001) and intellectual disability (57.14% compared with 
33.33%; p=0.0014) (see Table 3). The percentage of patients with enduring pharmacoresistance was 
greater in those with prior treatment with ≥ 5 ASMs (57.14% compared with 33.33%; p=0.0007) or 
previous epilepsy surgery or VNS (18.18 % compared with 4.55%; p=0.0065). Age, gender, duration of 
epilepsy and baseline seizure frequency were similar between ASM responders and non-responders. 
There were no differences in the mean number of clinic visits and ASM changes per patient between 
the two groups. Nine deaths were recorded in the ASM non-responder group, of which 4 were directly 
attributable to poorly controlled epilepsy (3 SUDEP and 1 status epilepticus).  
 
Within the ASM responder group, 33 (50%) were seizure free 12 months after a medication change, 
while the remaining patients had a greater than 75% reduction in seizure frequency 12 months after an 
intervention (see Table 2). Of note, 8 (12.12%) of these patients relapsed after a period of good seizure 
control. Within the ASM responder group 11 patients (16.67%) improved on ASM monotherapy. The 
remaining 55 patients (83.33%) responded to ASM combination therapy: 24 patients on 2 ASMs; 15 
patients on 3 ASMs; and 16 patients on 4 ASMs (see Figure 1). The ASM introductions temporally 
related to treatment response are shown in Figure 2. In 56 cases (84.85%), the response was noted at 
submaximal daily doses.  
 
The 10 most frequently added ASMs during the study period are shown in table 4. Lacosamide, 
perampanel, levetiracetam, zonisamide, and sodium valproate were the most frequently added ASMs. 
The mean and median daily dosages of the 10 most frequently prescribed ASMs were similar in both 
responders and non-responders. Certain ASMs, such as lamotrigine, phenytoin and topiramate were 
trialled more frequently prior to the study period (see Table 2 in supplementary materials). 
 
Figure 1 demonstrates the ASM combinations, categorized by their presumed mechanism of action, 
used in those who became seizure free or who had a greater than 75% reduction in seizure frequency. 
Of note, 53 of the 55 (96.36%) combination therapy responders were taking at least 2 drugs from 
different mechanistic groups (40 patients on ASMs from 2 different classes; 16 patients on ASMs from 










blocker) and synaptic vesicle protein 2A modulator (SV2A modulator) combination was observed most 
frequently (n= 28); followed by a Na channel blocker and ASM with multiple pharmacological targets 
(multi-target ASM) combination (n= 22); followed by a combination of a SV2A modulator and a multi-
target ASM (n= 15): followed by triple therapy with a Na channel blocker, a SV2A modulator and a multi-
target ASM (n= 11); followed by a combination of a Na channel blocker and perampanel (n=9). Of the 
11 patients who responded on monotherapy, 8 (72.73%) switched to an ASM with an alternative 
pharmacological target.  
Discussion 
In this study, we report a meaningful response to ASM therapy in a cohort of ‘real world’ patients with 
active DRE. Given the chronicity (median duration of epilepsy, 20.5 years; Table 1) and number of 
previously trialled ASMs (mean number of prior trialled ASMs, 5.2; Table 1), a poor overall prognosis 
would have been expected. Overall, 20% of patients achieved a meaningful improvement in seizure 
control one year after a medication adjustment, including 10% that resulted in seizure freedom. This 
and numerous other hospital-based 11,12,13,14,15 and long-term population-based10 studies demonstrate 
that it is worthwhile persisting with ASM trials in those with apparently DRE. Epilepsy surgery was 
clearly the most efficacious treatment, as 45.45% of patients (15/33) became seizure-free after surgery 
and an additional 30.3% (10/33) had a greater than 75% reduction in seizures after surgery. However, 
epilepsy surgery reponders comprised of only 7.75% of our DRE cohort overall, highlighting the 
previously mentioned barriers to epilepsy surgery: patient eligibility, patient preference and availability.      
 
Approximately 10% of all ASM introductions led to a meaningful treatment response of at least 75% 
seizure reduction. In contrast, only 1% of dose increases of an already-prescribed ASM led to improved 
seizure control (see Table 2). This concurs with our clinical experience, where if a substantial interim 
target ASM dose fails to produce an early clinical response, further dose increases rarely improve 
seizure control. This finding was observed in prospective studies where more patients became seizure 
free following ASM additions compared with dose increases.5,6,12 Of note, we recorded more than three 
times as many ASM introductions compared with ASM dose increases, which may reflect biased 
practice at our epilepsy clinic. In our practice, serum ASM concentrations are not used routinely  to 










the ASM. If a patient partially responded to an ASM, the dose was increased; if the ASM was ineffective 
at a submaximal dose, the ASM was usually withdrawn and another ASM trialled.      
 
The factors found to be associated with enduring pharmacoresistance (see Table 3) were combined 
focal and generalized epilepsy, intellectual disability, prior treatment with at least five ASMs and prior 
failed epilepsy surgery or active VNS therapy. ASM responders were more likely to have primary 
generalized epilepsy. These findings were in agreement with previous studies that found an association 
between pharmacoresistance and intellectual disability10,12,13,20 and the number of previously trialled 
ASMs.1,2,3,11,12,13,21 Prior studies indentified an associated between primary generalized epilepsy and 
favorable treatment responses in apparently DRE.11,22 Combined focal and generalized epilepsy was 
included as a new category in the latest iteration of the ILAE classification of the epilepsies,17 and as 
this category includes severe forms of epilepsy, including the epileptic encephalopathies, it 
unsurprisingly was associated with enduring pharmacoresistance. Numerous studies11,12,13 identified 
duration of intractability as a predictor of persistent refractory epilepsy, whereas in our cohort, duration 
of epilepsy was similar in ASM responders and non-responders. A similar finding was observed in a 
prospective cohort, where duration of pre-existing seizure freedom had no bearing on the likelihood of 
remaining seizure free after switching ASMs.5  
Our analysis of the ASM regimens used in those who experienced an apparent response yielded a 
number of observations. Approximately two thirds of the ASM additions temporally related to improved 
seizure control were agents licensed in the past two decades (lacosamide n=13; levetiracetam n=11; 
perampanel n=9; zonisamide n=7; eslicarbazepine n=4; brivarecetam n=1; Figure 2). Of the ASM 
additions that heralded reduced seizure frequency, almost 85% were maintained at submaximal daily 
doses. This supports pre-existing data, which demonstrated that patients who became seizure free on 
ASMs, did so on modest to moderate doses in most cases.23   Rational polytherapy was almost 
ubiquitous amongst ASMs responders, whether coincidental or otherwise. Over 95% of those who 
experienced significantly improved seizure control on combination therapy were taking at least 2 drugs 
with different mechanisms of action (see Figure 1). Combinations of sodium channel blockers  with 
SV2A modulators, multi-target ASMs or perampanel were observed in over two thirds of responders. In 












Approximately an eighth of ASM responders relapsed during the study period. In a prospective cohort 
study, almost 60% of patients relapsed after becoming seizure free for one year (5.9 years median 
follow-up).13 An unpredictable relapsing-remitting pattern of seizure frequency is seen in 16%-52.2% of 
patients with epilepsy.2,22 In patients with this epilepsy trajectory, periods of seizure freedom may be 
part of the natural history of the disease and it is debatable whether ASM manipulation prompts 
remission. It is estimated that among adult DRE patients, 5% per year enter seizure remission, 
irrespective of ASM changes.12,13   
We categorized a greater than 75% reduction in seizure frequency 12 months after a treatment 
intervention as a meaningful outcome, as we felt it captured a cohort with significantly reduced 
convulsive seizures, status epilepticus, injuries, hospitalizations and deaths. DRE is defined as failure 
to induce seizure freedom with ASMs and this is reflected in epilepsy research, where outcomes are 
typically dichotomized into absolute seizure freedom or not. 1,2,3,5,6,10,12,13,15  In surgically treated epilepsy 
patients, seizure freedom is the only outcome measure associated with improved quality of life.24,25 This 
has been indirectly demonstrated in two small studies of patients treated with ASMs only, where driving 
was the only outcome associated with improved quality of life (in most jurisdictions, driving is restricted 
until a person is 1 year seizure free).26,27 Severe, potentially injurious seizures contribute to anxiety and 
socially-avoidant behaviour, and are associated with reduced quality of life measures independent of 
seizure frequency.28,29 Infrequent convulsive seizures are a desirable outcome in DRE as it reduces the 
risk of SUDEP and death from status epilepticus. Uncontrolled epilepsy is associated with a significant 
mortality rate, demonstrated by the 4 epilepsy-related deaths in the non-responder group.  
 
A number of study limitations warrant mentioning. First, as a retrospective observational study the 
treatments were neither randomized nor blinded, introducing bias to the outcome evaluations and 
making inferences of causality difficult. Furthermore, the retrospective design meant that important data 
were not always available. Indeed, there was no standardized format of recording seizure frequency in 
the medical record and we relied on patient reports of seizure frequency, which may underestimate the 
true frequency. Second, as patients were typically treated with combinations of ASMs, attributing a 
clinical response to an individual intervention was challenging. In an effort to differentiate the 










fixed regimen of ASMs for at least six months prior to the study. Third, serum ASM levels were not 
routinely used to guide dosage adjustments. Prospective studies have failed to show that serum ASM 
concentrations relaibly correlate with ASM responsiveness18,19 and the doses reached in the present 
study were comparable to a treatment protocol utilized in an observational DRE treatment study.11 
Fourth, the senior author’s (D.J.C.) preference for rapid cycling of ASMs if an early response is not 
obtained may not be representative of current practice. Fifth, factors associated with 
‘pseudoresistance’, including poor compliance, substance misuse, inappropriate ASM prescribing for 
seizure type or suboptimal dosing may have been responsible for apparent ASM resistance.30 Indeed, 
in some cases PNES rather than epileptic seizures may have accounted for the main burden of disease. 
We excluded patients with a known history of PNES, substance misuse or nonadherence to ASMs, in 
an effort to control for these confounding factors.   
 
The ‘real world’ orientation of the study meant patients had heterogeneous treatment regimens, 
including combinations of ASMs that were introduced and withdrawn at varied points in time, epilepsy 
surgery and VNS. As most patients with DRE take multiple ASMs, prospective drug trials are 
challenging and the prospective ASM switching studies have questionable applicability to DRE, as they 
were conducted on patients with infrequent seizures, treated with ASM monotherapy.5,6 In the present 
study, the retrospective design and heterogeneity of treatments recorded limit the conclusions that can 
be drawn from individual interventions. Notwithstanding these limitations, our findings point towards a 
benefit in DRE with early ASM switching, if an improvement is not noted after a reasonable trial, on a 
modest dose. While, the long-term outcomes in epilepsy have remained largely unchanged despite the 
introduction of many new ASMs,3 it is plausible that certain combinations of ASMs may be more 
efficacious than others and the improved tolerability of newer agents may facilitate rational 
polytherapy.31 Beyond the well described therapeutic synergism between lamotrigine and sodium 
valproate, the literature supporting rational polytherapy is sparse.16 Isobolographic analysis32,33 and 
post-hoc analyses of lacosamide clinical trial data34 suggest that certain ASM combinations may have 
synergistic interactions. In the present study, responders were treated with combinations of ASMs with 











In conclusion, one fifth of our apparently DRE cohort experienced improved seizure control following 
ASM adjustment. Combined focal and generalized epilepsy, intellectual disability and prior treatment 
with more than five ASMs were more frequently observed in those with continued pharmacoresistance. 
Responders were more likely to have primary generalized epilepsy and to respond to a trial of a new 
ASM rather than adjustment in the dose of an existing ASM. The application of a systematic treatment 
protocol, where combinations of ASMs with different mechanistic targets are trialled and rotated early 
if a clinical response is not observed at a substantial target dose may yield better outcomes in chronic 
refractory epilepsy but this hypothesis warrants further investigation, ideally by prospective analysis. 
The deaths attributable to epilepsy highlight the significant consequences of uncontrolled epilepsy and 
that perseverance with ASM trials may be worthwhile to achieve palliative goals, such as reducing 
convulsive seizures or preventing status epilepticus. 
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Table 1: Baseline Patient Characteristics  
 
Characteristics n= 322 
Mean age (range), year 34.7 (16-70) 
Male (%) 176 (54.7) 
Duration of epilepsy, yearsa 
                              Mean 
                              Median 






                              Focal (%) 
                              Generalized (%) 
                              Combined (%) 
















Number of prior ASMs 
                              Mean 
                              Median 





Prior surgery (%)                               12 (3.7) 
Prior VNS (%) 36 (11.2) 
Seizure frequency, per month 
                              1-5 (%) 
                             6-10 (%) 





Duration of follow-up in study, year 
                              Mean 
                              Median 






a. In 13 patients, the exact duration of epilepsy was not known and was reported as ‘longstanding’ 
or ‘childhood epilepsy.’  
b. Epilepsy classified using the ILAE 2017 position paper.17 
















Number of interventions 
 
626 194 33 11 











>75% seizure reduction 1 year 
after intervention, including 






















































Table 3: Comparative analysis of patients who experienced meaningful improved seizure control 









Baseline characteristics    
Mean age (SD), years 34 (13.38) 35.14 (13.91) 0.5542 
Male, (%) 35 (53.03) 131 (56.71) 0.5960 
Duration of epilepsy ≥ 10 years (%)a 52 (78.79) 190 (82.25) 0.5241 
Epilepsy classificationb 
                   Focal (%) 
                Generalized (%) 
                   Combined (%) 


























≥ 5 ASMs previously taken (%) 22 (33.33) 132 (57.14) 0.0007 
Prior surgery/VNS (%) 3 (4.55) 42 (18.18) 0.0065 
Seizure frequency, per month 
                   1-5 (%) 
                6-10 (%) 













Interventions during study period    
Mean number of clinic visits (SD) 9.38 (4.56) 9.87 (6.09) 0.5446 
Mean ASM changes per patient (SD) 1.83 (1.37) 1.90 (1.80) 0.7701 
Mean ASM dose increases per patient 
(SD)  
0.52 (0.64) 0.60 (0.68)  0.3940 
Outcomes    
Death (%) 0 (0) 9 (3.90) - 
 
a. In 13 patients where duration of epilepsy was reported as ‘longstanding’ or ‘childhood epilepsy’, 
duration was categorized as greater than or equal to 10 years.   
b. Epilepsy classified using the ILAE 2017 position paper.15 
Table 4: 10 most frequently added ASMs in patients who experienced meaningful improved 
seizure control and those who remained drug resistant  
 
 ASM Responders  ASM Non-responders  



















dose     (mg) 
LAC 28 (42.4) 350 336.36 86 (37.2) 300 323.38 
PER 13 (19.7) 6 7.5 64 (27.7) 6 5.79 
LEV 22 (33.33) 2000 2347.22 39 (16.9) 2000 2219.29 










VLP 9 (13.6) 1400 1476 31 (13.4) 1500 1459.83 
CLB 4 (6.1) 15 16.25 30 (13) 20 20 
CBZ 8 (12.1) 700 895.24 25 (10.8) 800 804.87 
LTG 7 (10.6) 325 386.66 23 (10) 350 333.94 
ESL  6 (9.1) 800 950 23 (10) 800 953.33 




Abbreviations used in table 4: 
VPA= valproic acid; TPM= topiramate; ZNS= zonisamide; RUF= rufinamide; CBZ= carbamazepine; 
PHT= Phenytoin; LTG= lamotrigine; OXC= oxcarbazepine; ESL= eslicarbazepine; LAC= lacosamide; 













Figure titles and legends 
 
Figure 1 title: 
ASM combinations categorized by their presumed mechanism of action in those who experienced 





















Figure 1 legend: 
The ASM regimens used in those who experienced seizure freedom or greater than 75% reduction in 
seizure frequency, categorized by their presumed mechanisms of action are shown. Of the 11 patients 
who responded on monotherapy, 8 switched to an ASM with an alternative pharmacological target. 53 
of the 55 combination therapy ‘responders’ were taking at least 2 drugs from different mechanistic 
groups: 40 patients on ASMs from 2 different classes; 16 patients on ASMs from 3 different classes; 5 


















Figure 2 title:  































Figure 2 legend: 
The ASM introductions temporally related to treatment response are shown. In 56 cases, the response 
was noted at submaximal daily doses (represented by orange in graph). Approximately, 66% of the 
ASM additions temporally related to improved seizure control were agents licensed in the past two 
















































Abbreviations used in figure 1 and figure 2: 
Multi= multiple targets; Na= sodium channel blocker; SV2A= synaptic vesicle protein 2 modulation; 
GABA= GABAergic drugs; Ca= calcium channel blocker; AMPA= AMPA receptor blocker; K= potassium 
channel opener; VPA= valproic acid; TPM= topiramate; ZNS= zonisamide; FBM= Felbamate; RUF= 
rufinamide; CBZ= carbamazepine; PHT= Phenytoin; LTG= lamotrigine; OXC= oxcarbazepine; ESL= 
eslicarbazepine; LAC= lacosamide; LEV= levetiracetam; BRV= brivaracetam; PB= phenobarbital; 
TGB= tiagabine; VIG= vigabatrin; CLB= clobazam; ESX= ethosuximide; PGB= pregabalin; GBP= 
gabapentin; PER= perampanel; RTG= retigabine; AZA= acetazolamide. 
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